Walleye Capital LLC Lyell Immunopharma, Inc. Transaction History

Walleye Capital LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$2.78 - $8.09 $451,004 - $1.31 Million	-162,232 Reduced 73.4%	58,781 $203,000
Q3 2022 Nov 14, 2022	BUY	$5.54 - $8.27 $1.22 Million - $1.83 Million	221,013 New	221,013 $1.62 Million
Q2 2022 Aug 08, 2022	SELL	$3.68 - $6.8 $592,248 - $1.09 Million	-160,937 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$5.05 - $7.7 $752,136 - $1.15 Million	148,938 Added 1241.25%	160,937 $813,000
Q4 2021 Mar 03, 2022	BUY	$7.13 - $15.19 $85,552 - $182,264	11,999 New	11,999 $92,000

121

142M

18.1K

200

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $151M
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.